CHICAGO--(BUSINESS WIRE)--May 17, 2005--BARRX Medical, Inc. today announced the results of four studies evaluating safety, dosage response and efficacy of treating Barrett’s esophagus with the Halo360 system. The study results, presented at Digestive Disease Week(R) (DDW(R)), May 14-19, 2005, clearly demonstrate the benefits of the Halo360 system for the treatment of Barrett’s esophagus, a precancerous condition affecting the lining of the esophagus. Virender K. Sharma, M.D. of the Mayo Clinic in Scottsdale, Ariz., presented data from the Ablation of Intestinal Metaplasia (AIM-I) multi-center, prospective, randomized trial of 31 patients examining the safety, feasibility, tolerability and dose response in ablating short segment Barrett’s esophagus. After the procedure, patients underwent endoscopy at one, three, six and 12 months to determine the amount of Barrett’s removed. At six months, 75 percent of patients from one treatment group were cured of Barrett’s tissue. The authors conclude that the procedure is effective in the circumferential destruction of Barrett’s esophagus without significant complications, specifically no findings of stricture formation or buried glands.
